Siemens Healthcare Partners with Pfizer to Develop Companion Diagnostics
|
By LabMedica International staff writers Posted on 11 Feb 2014 |
|
Siemens Healthcare Diagnostics, of Siemens Healthcare (Erlangen, Germany), has entered into a collaboration agreement with the global, research-based pharmaceutical company Pfizer (New York City, NY, USA), to design, develop, and commercialize diagnostic tests for therapeutic products across Pfizer’s pipeline. Under the agreement, Siemens will be one of Pfizer's collaboration partners to develop and provide in vitro diagnostic tests for use in clinical studies and, potentially, eventual global commercialization with Pfizer products.
The Siemens Clinical Laboratory (SCL), a high-complexity testing laboratory focused on advancing personalized medicine, will develop the companion diagnostic tests under this partnership. The collaboration will leverage Siemens' worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories, and point-of-care settings to help enable diagnostics development.
"Companion diagnostics are an important enabler of targeted therapies for patients," said John Hubbard, senior vice president and Worldwide Head of Development Operations at Pfizer. “This agreement with Siemens Healthcare Diagnostics is another example of Pfizer's commitment to develop new precision medicines to address unmet clinical needs." Companion diagnostic tests are clinical tests linked to a specific drug or therapy, intended to assist physicians in making more informed and personalized treatment decisions for their patients. When used in the drug development process, companion diagnostics may help pharmaceutical companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.
"Our relationship with Pfizer marks a major milestone in Siemens' personalized medicine strategy," said Dr. Trevor Hawkins, Senior Vice President, Strategy & Innovations, Diagnostics Division, Siemens Healthcare; "We look forward to collaborating with Pfizer to realize the goal of advancing innovative solutions that change the way patient care is delivered and together shape the future of diagnostic medicine."
Related Links:
Siemens Healthcare
Pfizer
The Siemens Clinical Laboratory (SCL), a high-complexity testing laboratory focused on advancing personalized medicine, will develop the companion diagnostic tests under this partnership. The collaboration will leverage Siemens' worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories, and point-of-care settings to help enable diagnostics development.
"Companion diagnostics are an important enabler of targeted therapies for patients," said John Hubbard, senior vice president and Worldwide Head of Development Operations at Pfizer. “This agreement with Siemens Healthcare Diagnostics is another example of Pfizer's commitment to develop new precision medicines to address unmet clinical needs." Companion diagnostic tests are clinical tests linked to a specific drug or therapy, intended to assist physicians in making more informed and personalized treatment decisions for their patients. When used in the drug development process, companion diagnostics may help pharmaceutical companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.
"Our relationship with Pfizer marks a major milestone in Siemens' personalized medicine strategy," said Dr. Trevor Hawkins, Senior Vice President, Strategy & Innovations, Diagnostics Division, Siemens Healthcare; "We look forward to collaborating with Pfizer to realize the goal of advancing innovative solutions that change the way patient care is delivered and together shape the future of diagnostic medicine."
Related Links:
Siemens Healthcare
Pfizer
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Platelet Function Analyzer
PL-12
Latest Industry News
- Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
- Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business
- Agilent Completes Acquisition of Digital Pathology Platform Developer Proscia
- New Diagnostics Company Onvaro Formed to Expand Decentralized Testing
- Illumina Selected to Support National Genomics Study for Personalized Healthcare in Singapore
- Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk
- CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
- Real Diagnostics Adds Saliva-Based Periodontal Testing With SimplyTest Deal
- Collaboration Brings Tumor-Informed MRD Monitoring to Breast Cancer Care in Abu Dhabi
- Qiagen Agrees to Go Private Through EQT-Led Acquisition
- Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
- Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
- Myriad Genetics to Sell Prenatal Testing Portfolio to Labcorp
- Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch
- Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition
- Labcorp Acquisition to Strengthen Specialty Testing and Prostate Cancer Assessment
Channels
Clinical Chemistry
view channel
Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
Cerebrovascular disease damages blood vessels in the brain and can contribute to tissue injury, microbleeds, white matter damage, stroke, cognitive decline, and dementia. Identifying people at higher risk... Read more
Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
B-cell non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL), requires accurate identification to guide further evaluation, monitoring, and treatment. In 2026, an estimated 79,320 people in the U.... Read more
Molecular Diagnostics
view channel
Blood-Detected Chromosomal Changes May Refine Colorectal Cancer Risk Assessment
Colorectal cancer is among the most common cancers worldwide and a leading cause of cancer-related mortality. Identifying individuals at increased risk could help guide more targeted screening and prevention... Read more
AI Tool Automates Variant Curation and Interpretation for Cancer Whole-Genome Sequencing
Cancer whole-genome sequencing (WGS) provides a comprehensive view of cancer genomes, but interpreting the vast amount of data remains challenging. As WGS gains wider clinical adoption, variant curation... Read more
Hematology
view channel
New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients
Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more
Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers
Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read more
Microbiology
view channel
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read more
Pathology
view channel
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Technology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
